286 related articles for article (PubMed ID: 16614617)
1. [Antipsychotic drugs and cardiovascular safety: need for monitoring the QT interval].
Trojak B; Pinoit JM; André D; Bonin B; Gisselmann A
Presse Med; 2006 Apr; 35(4 Pt 2):699-704. PubMed ID: 16614617
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
3. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.
Vieweg WV; Wood MA; Fernandez A; Beatty-Brooks M; Hasnain M; Pandurangi AK
Drugs Aging; 2009; 26(12):997-1012. PubMed ID: 19929028
[TBL] [Abstract][Full Text] [Related]
4. QTc prolongation, torsades de pointes, and psychotropic medications.
Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
[TBL] [Abstract][Full Text] [Related]
5. Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death.
Wolbrette DL
Curr Cardiol Rep; 2004 Sep; 6(5):379-84. PubMed ID: 15306095
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic drugs and QT interval prolongation.
Zareba W; Lin DA
Psychiatr Q; 2003; 74(3):291-306. PubMed ID: 12918603
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced QT prolongation and sudden death.
Del Rosario ME; Weachter R; Flaker GC
Mo Med; 2010; 107(1):53-8. PubMed ID: 20222297
[TBL] [Abstract][Full Text] [Related]
8. [Lengthening of QT interval by antipsychotic drugs].
Haverkamp W; Deuschle M
Nervenarzt; 2006 Mar; 77(3):276, 278-80, 282-4 passim. PubMed ID: 16052325
[TBL] [Abstract][Full Text] [Related]
9. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes.
Vieweg WV; Wood MA
Psychosomatics; 2004; 45(5):371-7. PubMed ID: 15345781
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for QT prolongation associated with acute psychotropic drug overdose.
Miura N; Saito T; Taira T; Umebachi R; Inokuchi S
Am J Emerg Med; 2015 Feb; 33(2):142-9. PubMed ID: 25445869
[TBL] [Abstract][Full Text] [Related]
11. [QTc-prolonging drugs and the risk of sudden death].
Reingardiene D; Vilcinskaite J
Medicina (Kaunas); 2007; 43(4):347-53. PubMed ID: 17485963
[TBL] [Abstract][Full Text] [Related]
12. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
13. Concomitant use of antipsychotics and drugs that may prolong the QT interval.
Roe CM; Odell KW; Henderson RR
J Clin Psychopharmacol; 2003 Apr; 23(2):197-200. PubMed ID: 12640222
[TBL] [Abstract][Full Text] [Related]
14. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
[TBL] [Abstract][Full Text] [Related]
15. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic agents associated with QT interval prolongation.
Olsen KM
J Fam Pract; 2005 Jun; Suppl():S8-S14. PubMed ID: 15938993
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors.
Letsas KP; Efremidis M; Kounas SP; Pappas LK; Gavrielatos G; Alexanian IP; Dimopoulos NP; Filippatos GS; Sideris A; Kardaras F
Clin Res Cardiol; 2009 Apr; 98(4):208-12. PubMed ID: 19031039
[TBL] [Abstract][Full Text] [Related]
18. [Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].
Gury C; Canceil O; Iaria P
Encephale; 2000; 26(6):62-72. PubMed ID: 11217540
[TBL] [Abstract][Full Text] [Related]
19. Personalized, intuitive & visual QT-prolongation monitoring using patient-specific QTc threshold with pseudo-coloring and explainable AI.
Alahmadi A; Davies A; Vigo M; Jay C
J Electrocardiol; 2023; 81():218-223. PubMed ID: 37837739
[TBL] [Abstract][Full Text] [Related]
20. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update.
Beach SR; Celano CM; Sugrue AM; Adams C; Ackerman MJ; Noseworthy PA; Huffman JC
Psychosomatics; 2018; 59(2):105-122. PubMed ID: 29275963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
